CryoPort Inc. (CYRX)
NASDAQ: CYRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CYRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $964.87M
- EPS (TTM)
- -$0.90
- Dividend yield
- None
- 52-week range
- 7.61 – 21.78
- Day range
- 18.83 – 19.45
- Volume / Avg
- 814.78K / 843.80K
- Beta
- —
- Shares outstanding
- 50.65M
52-week range
CYRX stock today
Shares of CryoPort (CYRX) finished lower on Nov 20 at $19.05, a drop of 2.56% or $0.50 per share, versus the S&P 500's 3.70% decline. At this level, CYRX sits near the top of its 52-week range of $7.61 to $21.78: 12.5% below the high, set on Nov 11, 2026 and 150.3% above the low. CYRX is up 98.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 117.0%.
CryoPort has posted a net loss over the last twelve months (EPS of -$0.90), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CryoPort
Company profileCryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jerrell W. Shelton
- Headquarters
- Brentwood, TN
- Employees
- 684
- Website
- cryoportinc.com
Financial highlights
Full financialsIn fiscal 2025, CryoPort generated $176.2 million in revenue, up 12.4% from fiscal 2024. Net income was $78.3 million, for a net margin of 44.4% versus a median of -59.0% in the prior 5 years. Gross margin was 47.1% (up from 44.4%) and operating margin -20.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $176.18M | $156.77M | $168.66M | $237.28M | $222.61M |
| Growth | +12.38% | -7.05% | -28.92% | +6.59% | +182.87% |
| Net income | $78.30M | $-114.76M | $-99.59M | $-37.33M | $-275.53M |
| EPS (diluted) | $1.40 | $-2.49 | $-2.21 | $-0.93 | $-6.18 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$22.33+17.22%
- Strong buy 1
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.18 vs $-0.19
- Surprise
- +5.26%
CYRX news
All CYRX news- Cryoport Consensus Price Target Raised 10.69% to $21.95Nasdaq
- Cryoport raises 2026 revenue outlook to $197M-$199M as it targets 55% gross margin and 30% adjusted EBITDA long termSeeking Alpha
- Cryoport (CYRX) Q3 2026 Earnings Call TranscriptNasdaqCYRX, SUN
- CryoPort GAAP EPS of -$0.25 misses by $0.07, revenue of $50.2M beats by $1.51MSeeking Alpha
- Cryoport Reports Third Quarter 2026 Financial ResultsPR Newswire
- Cencora (COR) Surpasses Q4 Earnings and Revenue EstimatesNasdaqCOR, CYRX
- Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2NasdaqCAI, CYRX
CryoPort peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SPTXSeaport Therapeutics Inc. | 18.05 | -1.47% | $966.23M | vs CYRX |
| OMEROmeros Corporation | 13.21 | -5.71% | $983.66M | vs CYRX |
| MLTXMoonLake Immunotherapeutics Class A | 11.07 | +0.36% | $942.13M | vs CYRX |
| SVRASavara Inc. | 4.26 | -18.23% | $939.86M | vs CYRX |
| ANROAlto Neuroscience Inc. | 25.37 | -4.30% | $1.02B | vs CYRX |
| AKTSAktis Oncology Inc. | 16.15 | -1.52% | $901.14M | vs CYRX |
| CTYCity Therapeutics Inc. | 19.32 | +5.29% | $1.03B | vs CYRX |
| NKTRNektar Therapeutics | 30.20 | -7.19% | $1.03B | vs CYRX |
Indexes, lists and sector
CryoPort stock FAQ
What is CryoPort's stock price today?
CYRX last traded at $19.05 as of Nov 20, 4:00 PM EST, down 2.56% on the day. Prices are delayed at least 15 minutes.
Does CryoPort pay a dividend?
No. CryoPort does not currently pay a regular cash dividend.
Who is CryoPort's CEO?
Mr. Jerrell W. Shelton is the chief executive officer of CryoPort Inc., which has about 684 employees.
Has CYRX ever split its stock?
Yes. The most recent CYRX stock split was a 1-for-12 split on May 19, 2015, one of 2 splits on record.
What is the CYRX 52-week high?
The 52-week high for CYRX is $21.78 and the 52-week low is $7.61. The stock is currently 12.5% below its high.